Natco Pharma (BOM:524816) EV-to-EBIT : 10.02 (As of May. 28, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Natco Pharma's Enterprise Value is ₹169,560 Mil. Natco Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹16,927 Mil. Therefore, Natco Pharma's EV-to-EBIT for today is 10.02.

The historical rank and industry rank for Natco Pharma's EV-to-EBIT or its related term are showing as below:

BOM:524816' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.12 Med: 21.87 Max: 69.32
Current: 11.08

During the past 13 years, the highest EV-to-EBIT of Natco Pharma was 69.32. The lowest was 9.12. And the median was 21.87.

BOM:524816's EV-to-EBIT is ranked better than
69.01% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs BOM:524816: 11.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Natco Pharma's Enterprise Value for the quarter that ended in Mar. 2024 was ₹0 Mil. Natco Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹16,927 Mil. Natco Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

Natco Pharma EV-to-EBIT Historical Data

The historical data trend for Natco Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma EV-to-EBIT Chart

Natco Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EV-to-EBIT

Get a 7-Day Free Trial

14.76

24.67

62.65

10.71

Natco Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															10.71	12.59	10.83	9.49	-

Competitive Comparison of Natco Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Natco Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Natco Pharma's EV-to-EBIT falls into.

Natco Pharma EV-to-EBIT Calculation

Natco Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	169559.878	/	16927
	=	10.02

Natco Pharma's current Enterprise Value is ₹169,560 Mil.
Natco Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16,927 Mil.

Natco Pharma (BOM:524816) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Natco Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	16927	/	0
	=	%

Natco Pharma's Enterprise Value for the quarter that ended in Mar. 2024 was ₹0 Mil.
Natco Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16,927 Mil.

Natco Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Natco Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Natco Pharma (BOM:524816) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » EV-to-EBIT

Traded in Other Exchanges

NATCOPHARM:India

Address

Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034

Website

https://www.natcopharma.co.in

Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines